Key Points
Even if valuations are at a premium, which it has always commanded, the second half numbers should be relatively better."ETMarkets.com..
Mayuresh Joshi, Head, Equity Research India, William O Neil, says a lot of underperformance in pharma was very evident a few quarters back..
A lot of speciality launches are happening and are expected to get launched across the pharma companies in the next few quarters and years as we speak, which gives them better margin stability...
As clearances are coming through, the entire speciality pipeline both through ANDAs and FDFs which will get filed, will provide better comfort in terms of better margin products coming through from their own facilities where a large part of the backward integration for most molecules as an example for Dr. Reddy's is expected to be conditioned in the next few quarters will probably aid earnings growth...
As we head into the next few quarters and as advances growth starts showing a strong uptick where HDFC Bank counter numbers have been very, very conservative..
You might be interested in
HDFC Bank's total advances record 17% growth to ₹16,005 bn in Q4FY23, domestic retail loans up 21%
03, Apr, 23HDFC Bank garnered advances of approximately ₹16,005 billion --- rising by 16.9% from ₹13,688 billion in the same quarter last year. While the growth stood at 6.2% from advances of ₹15,068 billion in the December 2022 quarter.